Cancer therapy sensitizer

Details Cancer therapy sensitizer Cancer therapy sensitizer

2009-11-25

2011-12-06

Aeder, Sean (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S007100, C514S04400A

Reexamination Certificate

active

08071294

ABSTRACT:
The present invention relates to compositions and methods for sensitizing cancer therapy. The invention provides such compositions comprising a SPARC family polypeptide or polynucleotide, as well as recombinant cells containing a SPARC family polypeptide or polynucleotide. The compositions and methods of the invention are useful in in vitro study of cancer therapy resistance, as well as ex vivo and in vivo therapy of cancer.

REFERENCES:
patent: 5674743 (1997-10-01), Ulmer
patent: 5962320 (1999-10-01), Robinson
patent: 6187307 (2001-02-01), Cohen
patent: 6194205 (2001-02-01), Staege et al.
patent: 6239326 (2001-05-01), Howe
patent: 6316193 (2001-11-01), He et al.
patent: 6387664 (2002-05-01), Ikemoto
patent: 6406693 (2002-06-01), Thorpe et al.
patent: 6475784 (2002-11-01), Papkoff
patent: 7485414 (2009-02-01), Lorens et al.
patent: 2002/0169121 (2002-11-01), Ronai
patent: 2003/0082228 (2003-05-01), Flowers et al.
patent: 2003/0180306 (2003-09-01), Hill et al.
patent: 2004/0229338 (2004-11-01), King
patent: WO 98/29138 (1998-07-01), None
patent: WO 00/72679 (2000-12-01), None
patent: WO 01/20989 (2001-03-01), None
patent: WO 01/25397 (2001-04-01), None
patent: WO 01/81631 (2001-11-01), None
patent: WO 02/02771 (2002-01-01), None
patent: WO 02/089772 (2002-11-01), None
patent: WO 2004/005883 (2004-01-01), None
patent: WO 2004/016758 (2004-02-01), None
patent: WO 2005/026357 (2005-03-01), None
Alliel et al.,Eur. J. Biochem., 214, 347-350 (1993).
Arber et el.,Gastroenterology, 118, 1045-1050 (2000).
Bellahcène et al.,American Journal of Pathology, 146(1), 95-100 (Jan. 1995).
Bendik et al.,Cancer Res., 58 (4), 626-629 (Feb. 15, 1998).
Bornstein,J. Cell Biol., 130, 503-506 (1995).
Bradshaw et al.,J. of Clinical Investigation, 107(9), 1049-1054 (May 2001).
Bradshaw et al.,PNAS, 100(10), 6045-6050 (May 13, 2003).
Brown et al.,Gynecologic Oncology, 75: 25-33 (1999).
Carmichael et al.,Cancer Res., 47, 936-942 (Feb. 15, 1987).
Cree et al.,Curr. Opn. Invest. Drugs, 3 (4), 641-647 (2002).
Chlenski et al.,Cancer Res., 62, 7357-7363 (Dec. 2002).
de las Alas et al.,J. Natl. Cancer Inst., 89 (20), 1537-1541 (Oct. 15, 1997).
Dhanesuan et al.,Breast Cancer Research and Treatment, 75, 73-85 (2002).
Eltabbakh, Gamal H., J. Surg. Oncol., 73, 148-152 (2000).
Fillpits et al.,Br. J. Cancer, 75 (2), 208-212 (1997).
Folkman, Judah,N. Engl. J. Med., 333 (26), 1757-1763 (1995).
Georgiou,Current Opinion in Biotechnology, 7, 190-197 (1996).
Gilbert et al.,Kidney International, 48, 1216-1225 (1995).
Guermah et al.,Proc. Natl. Acad. Sci. USA, 88, 4503-4507 (May 1991).
Hasselaar et al.,J. of Biological Chemistry, 266(20), 13178-13184 (Jul. 15, 1991).
Hasselaar et al.,J. Cell. Biochem., 49, 272-283 (1992).
Hebbes et al.,Mol. Immunol., 26 (9), 865-873 (1989).
Hohenadl et al.,J. Biological Chemistry, 270(40), 23415-23420 (Oct. 6, 1995).
Iruela-Arispe et al.,Mol. Biol. Cell, 6, 327-343 (Mar. 1995).
Jendraschak et al.,Seminars in Cancer Biology, 7, 139-146 (1996).
Johnston et al.,Neuron, 4 (1), 165-176 (Jan. 1990).
Johnstone et al.,Cell, 108, 153-164 (Jan. 25, 2002).
Kamesaki H.,Int. J. Hematology, 68, 29-43 (1998).
Kelm et al.,J. Biol. Chem., 269 (48), 30147-30153 (1994).
Kim et al.,J. Korean Med. Sci., 13, 652-657 (1998).
Kupprion et al.,J. Biol. Chem., 273 (45), 29635-29640 (1998).
Lane et al., J. Biol. Chem., 267 (23), 16736-16745 (Aug. 1992).
Lane et al.,FASEB J., 8, 163-173 (Feb. 1994).
Lane et al., J. Cell Biol., 125 (4), 929-943 (May 1994).
Lankat-Buttgereit et al.,FEBS Lett., 236, 352-356 (Aug. 1988).
Latvala et al.,Exp. Eye Res., 63, 579-584 (1996).
Le Bail et al.,J. Pathol., 189, 46-52 (1999).
Ledda et al.,Nature Medicine, 3 (2), 171-176 (1997).
Lehnert, Manfred,Anticancer Res., 18, 2225-2226 (1998).
Li et al.,Clin. &Exp. Metastasis, 17, 423-429 (1999).
Lin et al.,Mol. Pharm., 56, 390-395 (1999).
Lussier et al,J. Cell. Biochem., 81, 463-476 (2001).
Ma et al.,Antisense&Nucleic Acid Drug Development, 8, 415-426 (1998).
Maillard et al.,Bone, 13, 257-264 (1992).
Makin, Guy,Expert Opn. Ther. Targets, 6 (1), 73-84 (2002).
Mason et al.,EMBO J., 5 (7),1465-1472 (Jul. 1986).
Mason et al.,EMBO J., 5 (8),1831-1837 (Aug. 1986).
Nair et al.,J. Immunol., 165 (12), 6949-6955 (2000).
Paley et al.,Gyn. Oncol., 78, 336-341 (2000).
Parikh et al.,Biotechniques, 24, 428-431 (Mar. 1998).
Pichler et al.,Am. J. of Pathology, 148(4), 1153-1167 (Apr. 1996).
Porte et al.,Int. J. Cancer, 64, 70-75 (1995).
Porte et al.,Clin. Cancer Res., 4, 1375-1382 (Jun. 1998).
Porter et al.,J. Histochem. &Cytochem. 43(8), 791-800 (1995).
Qi et al., Nuc. Acids Res., 29 (22), e116 (2001).
Raines et al.,Proc. Natl. Acad. Sci. USA, 89, 1281-1285 (Feb. 1992).
Rempel et al.,Clinical Cancer Research, 5, 237-241 (Feb. 1999).
Ringborg et al.,Acta Oncol., 76-80 (1996).
Sage et al.,J. Biol. Chem., 266 (23), 14831-14834 (Aug. 1991).
Sage E. Helene,Biochem. Cell Biol., 70, 579-592 (1992).
Sage et al.,J. Cellular Biochemistry, 57, 127-140 (1995).
Sage et al.,J. Biological Chemistry, 278(39) 37849-37857 (Sep. 26, 2003).
Schulz et al., Am. J. Path, 132 (2), 233-238 (Aug. 1988).
Schwartz et al.,J. Immunol., 135 (4), 2598-2608 (1985).
Shea et al.,Cancer Res., 48, 527-533 (Feb. 1, 1988).
Shibanuma et al.,Eur. J. Biochem., 217, 13-19 (1993).
Skoudy et al.,Biochem. J., 317, 279-284 (1996).
Stein et al.,J. Natl. Cancer Inst., 88 (19), 1383-1392 (Oct. 2, 1996).
Stites and Terr (eds.)Basic and Clinical Immunology, 7thed., East Norwalk, Connecticut, Appleton and Lange (1991).
St. Croix et al.,Nat. Med., 2, (11) 1204-1210 (Nov. 1996).
Strandjord et al.,Am. J. Respir. Cell Mol. Biol., 13, 279-287 (1995).
Swaroop et al.,Genomics, 2, 37-47 (1988).
Tanigawa et al.,Cancer Res., 42, 2159-2164 (Jun. 1982).
Takahashi et al.,Obesity Res., 9(7) 388-393 (Jul. 2001).
Termine et al.,Cell, 26, 99-104 (Oct. 1981).
Thomas et al.,Clinical Cancer Res., 6, 1140-1149 (Mar. 2000).
Tockman et al.,Cancer Res., 52, 2711s-2718s (1992).
Vannahme et al.,J. Biol. Chem., 277 (41), 37977-37986 (Oct. 11, 2002).
Vial et al.,Oncogene, 19, 1772-1782 (2000).
Waldman et al.,Nature, 381, 713-716 (Jun. 20, 1996).
Weisenthal et al.,Recent Results in Cancer Res., 94, 161-173 (1984).
Weisenthal et al.,Cancer Treatment Reports, 69 (6), 615-632 (Jun. 1985).
Weisenthal, L.M.,Drug Resistance in Leukemia and Lymphoma: The Clinical Value of Laboratory Studies, pp. 415-423, Harwood Academic Publishers (1993).
Weisenthal,Contrib. Gyn. Obstet. 19, 82-90 (1994).
Weisenthal, Larry M.,Chemosensitivity Testing in Gynecologic Malignancies and Breast Cancer, v. 19, pp. 82-90, Basel, Karger (1994).
Werb,Cell, 91, 439-442 (Nov. 14, 1997).
Wolfsberg et al.,J. Cell Biology, 131(2) 275-278 (Oct. 1995).
Yiu et al.,American Journal of Pathology, 159(2): 609-622 (Aug. 2001).
Yamanaka et al.,J. Urology, 166, 2495-2499 (Dec. 2001).
Yan et al.,J. Histochemistry&Cytochemistry, 47(12), 1495-1505 (1999).

Affiliated with

Also associated with

Rating

Cancer therapy sensitizer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer therapy sensitizer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer therapy sensitizer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4309285